Dimethyl 2-(4-hydroxyphenyl)-3-(2-methylpropyl)but-2-enedioate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: Dimethyl 2-(4-hydroxyphenyl)-3-(2-methylpropyl)but-2-enedioate
• 化学式: C₁₆H₂₀O₅
• 分子量: 292.33
• InChiKey: ADNALORXBBMMON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA
  申请人：Kuo Yueh-Hsiung

  公开号：US20100130584A1

  公开（公告）日：2010-05-27

  Compounds isolated from the fruiting body of A. camphorata in a solid culture or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds or pharmaceutically acceptable salts thereof.
• USE OF NOVEL COMPOUNDS FROM FRUITING BODY OF ANTRODIA CAMPHORATA FOR TREATING AN INFLAMMATORY DISORDER
  申请人：Kuo Yueh-Hsiung

  公开号：US20120149753A1

  公开（公告）日：2012-06-14

  Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170042912A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.
• US7932285B2
  申请人：——

  公开号：US7932285B2

  公开（公告）日：2011-04-26
• US8148420B2
  申请人：——

  公开号：US8148420B2

  公开（公告）日：2012-04-03